Prime Medicine (PRME) Total Current Liabilities (2021 - 2026)
Prime Medicine's (PRME) quarterly Total Current Liabilities came in at $36.3 million in Q1 2026, up 5.84% YoY from $34.3 million in Q1 2025, and down 3.09% on a QoQ basis from $37.4 million in Q4 2025.
Prime Medicine (PRME) Total Current Liabilities (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Total Current Liabilities data on file, last reported at $36.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 5.84% year-over-year to $36.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.3 million (up 5.84% YoY) and the FY2025 annual result came in at $37.4 million, down 1.35% from the prior year.
- Total Current Liabilities declined to $36.3 million in Q1 2026, from $37.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $56.4 million in Q4 2023 to a low of $20.7 million in Q2 2024.
- A 5-year average of $33.0 million and a median of $34.3 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 53.93% — and 2023, when it jumped 111.21%.
- Tracing PRME's Total Current Liabilities over 5 years: stood at $26.7 million in 2022, then jumped by 111.21% to $56.4 million in 2023, then slumped by 32.72% to $38.0 million in 2024, then retreated by 1.35% to $37.4 million in 2025, then fell by 3.09% to $36.3 million in 2026.
- The last three Total Current Liabilities figures came in at $36.3 million (Q1 2026), $37.4 million (Q4 2025), and $35.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 31.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.69 Mn |
| Mar 31, 2026 | 36.29 Mn |
| Dec 31, 2025 | 37.45 Mn |
| Sep 30, 2025 | 35.02 Mn |
| Jun 30, 2025 | 34.11 Mn |
| Mar 31, 2025 | 34.29 Mn |
| Dec 31, 2024 | 37.96 Mn |
| Sep 30, 2024 | 37.88 Mn |
| Jun 30, 2024 | 20.75 Mn |
| Mar 31, 2024 | 24.44 Mn |
| Dec 31, 2023 | 56.42 Mn |
| Sep 30, 2023 | 39.37 Mn |
| Jun 30, 2023 | 28.72 Mn |
| Mar 31, 2023 | 23.87 Mn |
| Dec 31, 2022 | 26.71 Mn |
| Sep 30, 2022 | 22.22 Mn |
| Dec 31, 2021 | 57.98 Mn |